Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.67 |
| ▸ | MMP3 | P08254 | 16/20 | 0.67 |
| ▸ | MMP13 | P45452 | 11/20 | 0.67 |
| ▸ | MMP7 | P09237 | 10/20 | 0.67 |
| ▸ | MMP9 | P14780 | 8/20 | 0.67 |
| ▸ | MMP8 | P22894 | 6/20 | 0.60 |
| ▸ | MMP2 | P08253 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5636340 | 0.88 | MMP2 (0.57) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL7246512 | 0.87 | MMP3 (0.54) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL7245645 | 0.82 | MMP1 (0.51) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL5639174 | 0.80 | MMP1 (0.69) | MMP1MMP3MMP13MMP7MMP9 | |
| Hydrochloric Acid SCHEMBL7251560 | 0.80 | MMP1 (0.98) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL6345861 | 0.79 | MMP3 (0.62) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL5636820 | 0.78 | MMP1 (0.60) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL7235965 | 0.78 | MMP3 (0.71) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL3495253 | 0.77 | MMP8 (0.80) | MMP1MMP3MMP13MMP7MMP8 | |
| SCHEMBL29697336 | 0.77 | MMP8 (0.80) | MMP1MMP3MMP13MMP7MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223751-B2 | Sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same | KOLON IND. INC. (KR) | 2007-05-29 | — | — | US | disclosed |
| EP-1389204-A4 | NOVEL SULFONAMIDE DERIVATIVES, INTERMEDIATE THEREOF, ITS PREPARATION METHODS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOLON INC (KR) | 2005-03-23 | — | — | EP | disclosed |
| US-20040138206-A1 | Novel sulfonamide derivatives, intermidiate thereof, its preparation methods, and pharmaceutical composition comprising the same | KOLON LIFE SCIENCE, INC. (KR) | 2004-07-15 | — | — | US | disclosed |
| EP-1389204-A1 | NOVEL SULFONAMIDE DERIVATIVES, INTERMEDIATE THEREOF, ITS PREPARATION METHODS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Kolon Ind. Inc. (KR) | 2004-02-18 | — | — | EP | disclosed |
| US-6509337-B1 | A method of treating a mammalian disease condition mediated by metalloproteinase activity which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound as defined in claim 1 or a pharmaceutically | PFIZER INC. | 2003-01-21 | — | — | US | disclosed |
| WO-2002088115-A1 | NOVEL SULFONAMIDE DERIVATIVES, INTERMEDIATE THEREOF, ITS PREPARATION METHODS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOLON IND. INC. (KR) | 2002-11-07 | — | — | WO | disclosed |
| EP-0821671-B1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS | PFIZER (US) | 2000-12-27 | — | — | EP | disclosed |
| US-5861510-A | Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors | PFIZER INC (US) | 1999-01-19 | — | — | US | disclosed |
| EP-0821671-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS | PFIZER INC. (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033172-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS | PFIZER INC. (US) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138206-A1 | Novel sulfonamide derivatives, intermidiate thereof, its preparation methods, and pharmaceutical composition comprising the same | MMP1, MMP7, STS | MMP1 1/4885MMP3 20/4885MMP13 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.